QR-504a / ProQR - LARVOL DELTA

Fuchs Focus: Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3 (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: ProQR Therapeutics | Trial completion date: Oct 2023 ➔ Apr 2022 | Recruiting ➔ Withdrawn | Trial primary completion date: Oct 2023 ➔ Apr 2022

Biomarker • Trial completion date • Trial primary completion date • Trial withdrawal • Ophthalmology • TCF7L2

Fuchs Focus: Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3 (clinicaltrials.gov) - P1; N=9; Recruiting; Sponsor: ProQR Therapeutics

Biomarker • Clinical • New P1 trial • Ophthalmology • TCF7L2